Tag: MindMed - Page 7 - Psychedelic Alpha

Read more about the article MindMed’s LSD Neutralizer Study Begins

MindMed’s LSD Neutralizer Study Begins

Post published:February 17, 2021
Post category:Press Release

Read more about the article MindMed Signs Partnership with Swiss Psychedelic Drug Discovery Startup MindShift Compounds AG, Expands Development Pipeline and IP Portfolio with Next-Gen Psychedelic and Empathogenic Compounds

MindMed Signs Partnership with Swiss Psychedelic Drug Discovery Startup MindShift Compounds AG, Expands Development Pipeline and IP Portfolio with Next-Gen Psychedelic and Empathogenic Compounds

Post published:February 11, 2021
Post category:Press Release

Read more about the article MindMed Streamlines Leadership with Further Emphasis on Integrating Psychedelic Drug Development with Digital Medicines and Therapeutics

MindMed Streamlines Leadership with Further Emphasis on Integrating Psychedelic Drug Development with Digital Medicines and Therapeutics

Post published:February 2, 2021
Post category:Press Release

Read more about the article MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA and LSD

MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA and LSD

Post published:January 20, 2021
Post category:Press Release

Read more about the article MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience

MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience

Post published:January 14, 2021
Post category:Press Release

Read more about the article MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Digital Clinical Markers

MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Digital Clinical Markers

Post published:January 12, 2021
Post category:Press Release

Read more about the article MindMed Closes Upsized Financing of CAD $92.1m (USD $72.7m) to Meet High Investor Demand

MindMed Closes Upsized Financing of CAD $92.1m (USD $72.7m) to Meet High Investor Demand

Post published:January 7, 2021
Post category:Press Release

Read more about the article MindMed Files Final Prospectus In Connection With Bought Deal Equity Financing

MindMed Files Final Prospectus In Connection With Bought Deal Equity Financing

Post published:January 4, 2021
Post category:Press Release

Read more about the article MindMed Files Preliminary Prospectus In Connection With Bought Deal Equity Financing

MindMed Files Preliminary Prospectus In Connection With Bought Deal Equity Financing

Post published:December 21, 2020
Post category:Press Release

Read more about the article MindMed Upsizes Previously Announced Bought Deal Public Offering

MindMed Upsizes Previously Announced Bought Deal Public Offering

Post published:December 15, 2020
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.